Singapore-based Cuprina Holdings announced a 1-for-8 consolidation of its ordinary shares, a move set to take effect around May 27, 2026, as it seeks to comply with Nasdaq listing rules.
“This action is an important step toward maintaining our Nasdaq listing and enhancing the Company’s long‑term financial flexibility,” Cuprina Chief Executive Officer David Quek said. “This approval reflects our shareholders’ support for strengthening Cuprina’s capital markets position.”
The reverse stock split will convert every eight Class A and Class B shares into one share, respectively, raising the par value from $0.001 to $0.008 per share. The consolidation aims to satisfy Nasdaq Marketplace Rule 5550(a)(2), which requires shares to maintain a minimum bid price.
The action, approved by the board on April 21 and shareholders on May 14, will not alter any shareholder’s percentage interest, as fractional shares will be rounded up. Following the split, the company’s Class A shares will trade under the same “CUPR” symbol but with a new CUSIP number, G2592E110.
Investor Reactions
The announcement comes as institutional ownership shows mixed signals. In the first quarter of 2026, Citadel Advisors LLC added 37,281 shares and XTX Topco Ltd acquired 35,457 shares, according to regulatory filings. However, other institutional investors have reduced their positions, with firms like Stonex Group and Two Sigma Securities eliminating their holdings entirely in the preceding quarters.
The consolidation is a critical move for the biomedical company, which specializes in products for chronic wounds, infertility, and medical waste recycling. By boosting its share price, Cuprina aims to stabilize its position on the Nasdaq and maintain access to capital markets. Investors will be watching whether the move can restore confidence when trading begins on a post-split basis on May 27.
This article is for informational purposes only and does not constitute investment advice.